Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02285075
Other study ID # SVDC Temocillin 1
Secondary ID
Status Completed
Phase Phase 4
First received November 2, 2014
Last updated January 3, 2016
Start date June 2011
Est. completion date December 2014

Study information

Verified date January 2016
Source AZ Sint-Jan AV
Contact n/a
Is FDA regulated No
Health authority Belgium: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The current study aimed to explore the pharmacokinetics of temocillin in patients treated with haemodialysis and to demonstrated whether or not the pharmacodynamics target of a time above a MIC of 16 mg/L of more than 40 and 60 % of the dosing interval could be obtained with a dosing schedule of 1 gram/24 hours, 2 gram/48 hours and 3 gram/72 hours, all of these doses given after haemodialysis sessions only.


Description:

Background: Temocillin is a renally cleared penicillin with long serum half-live and potent activity against most gram-negative bacteria, making it an ideal candidate for treatment given on dialysis days only of severe gram-negative infections in patients with ESRD treated with haemodialysis.

Endpoints:

Primary: The current study aimed to demonstrated by measurement of AUC whether or not the pharmacodynamics target of a time above a MIC of 8 and 16 mg/L of more than 40 and 60 % of the dosing interval could be obtained with a dosing schedule of 1 gram/24 hours, 2 gram/48 hours and 3 gram/72 hours, all of these doses given after haemodialysis sessions only.

Secondary: Key pharmacokinetic and dialytic parameters were determined as previously described16. The following parameters were recorded: the volume of distribution Vd (determined as Vd = dose / (Tempeak - Temtrough) in liter); the Vd/Wt (in liter/kg body weight); the non-dialysis clearance of temocillin (Ke(non-dialysis) = [ln(Tempeak) - ln(Tempre)] / time between peak level and start of next dialysis); the non-dialysis half-life (T1/2(non-dialysis) = 0.693 / Ke(non-dialysis) in hours); the dialysis clearance of temocillin (Ke(dialysis) = [ln(Tempre) - ln(Tempost)] / dialysis duration); the dialysis half-life (T1/2(dialysis) = 0.693 / Ke(dialysis) in hours); the Urea Reduction Ratio (URR = (BUNpre - BUNpost) / BUNpre); the Temocillin Reduction Ratio TRR = (Tempre - Tempost) / Tempre); the Temocillin Removal Ratio (the total amount of temocillin recovered in the dialysate, based on the area under the curve of the temocillin removal rate and the treatment time); and the AUC of temocillin. For all PK/PD analysis, the non-compartmental method using RStudio 0.98.501 with R 3.0.2 software was used.

Methods: Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with intermittent haemodialysis and temocillin. Blood samples were drawn just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval. Patients were followed for 1 to 6 subsequent AUC. Dialysate samples were taken 1, 2, 3 and 4 h after the start of dialysis. All samples were taken from an arterial or venous catheter, after thorough rinsing. Serum (obtained by centrifugation after blood clotting) and dialysate was frozen (-80 C) immediately after sampling until analysis.

Temocillin total and free concentrations were determined with high performance liquid chromotography(HPLC) with a LiChrospher 100 RP-18 5 μm column (Merck AG), using an elution buffer 100 mM Na acetate buffer pH 7/acetonitrile (95:5, v/v), a flow rate 1 mL/min and a Waters 2690 Alliance System (Waters Corp., Milford, MA, USA), with quantification at 235 nm as previously described.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- all patients under treatment with haemodialysis for ESRD for whom a treatment with temocillin was indicated according to the attending physician were eligible for the study.

Exclusion Criteria:

- an age of less than 18 years

- an estimated life-expectance of < 24 hours due to major co-morbid conditions

- pregnancy

- an IgE-mediated allergy to penicillins

- patients not giving informed consent.

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
temocillin PK/PD in haemodialysis
Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T > MIC of 8 and 16 mg/L).

Locations

Country Name City State
Belgium AZ Sint-Jan Brugge Oostende AV Brugge
Belgium Louvain Drug Research Institute (LDRI) Brussels

Sponsors (4)

Lead Sponsor Collaborator
AZ Sint-Jan AV Ana Miranda Bastos, Louvain drug research institute, belgium, Francoise Van Bambeke, Louvain drug research institute, belgium, Paul Tulkens, Louvain drug research institute, belgium

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Miranda Bastos AC, Vandecasteele SJ, Tulkens PM, Spinewine A, Van Bambeke F. Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients. J Pharm Biomed Anal. 2014 Mar — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary % of the dosing interval time above an MIC of 8 and 16 mg/L (% T>MIC 8 or 16 mg/L) Is T > MIC 8 and 16 mg/ML > 40 or 60 % two to ten days No
Secondary Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis Vd (volume of distribution) two to ten days No
Secondary Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis T1/2 (serum half life, on and of dialysis) two to ten days No
Secondary Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis Temocillin clearance (renal and non-renal) two to ten days No
Secondary Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis Temocillin reduction rate two to ten days No
Secondary Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis temocillin removal rate two to ten days No
Secondary Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis temocillin protein binding two to ten days No
See also
  Status Clinical Trial Phase
Completed NCT00723502 - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients Phase 2
Completed NCT00177814 - Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Suspended NCT00563134 - A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult N/A
Active, not recruiting NCT05171257 - Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit
Completed NCT03160040 - A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
Completed NCT02962934 - An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT
Not yet recruiting NCT06135350 - Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV Phase 2
Enrolling by invitation NCT04055922 - Comparison of Solid Organ Transplant
Completed NCT00490477 - The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial Phase 3
Recruiting NCT04861922 - Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection Phase 3
Completed NCT01732250 - Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem Phase 4
Completed NCT00406198 - Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Phase 4
Recruiting NCT06086626 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants Phase 2
Withdrawn NCT04785924 - Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Phase 4
Completed NCT03182504 - A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants Phase 1
Not yet recruiting NCT04917380 - The Clinical Character,Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Completed NCT03397914 - Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections Phase 4
Completed NCT02088840 - Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant
Recruiting NCT01600768 - Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients N/A